Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0000950170-25-045295

Chief Scientific Officer sold 2,631 shares at $6.60 ($17,365)

  • Chief Scientific Officer acquired 2,631 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
SCIASCIA THOMAS Chief Scientific Officer 2025-03-25 Option exercise +2,631 $1.43 $3,762 224,004 D
SCIASCIA THOMAS Chief Scientific Officer 2025-03-25 Sale −2,631 $6.60 $17,365 221,373 D
Derivatives
SCIASCIA THOMAS Chief Scientific Officer 2025-03-25 Option exercise · Stock Option (right to buy) −2,631 0 D
Open-market sales · 2,631 sh · avg $6.60 · $17,365
Loading xslF345X05/ownership.xml…